The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients

The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome

(2009) C. FRÉRE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Effect of CYP2C19 *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians

(2008) Nicole G. Hunfeld et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

(2008) R. Michael Baldwin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

(2008) I. Rudberg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

(2008) Staffan Ohlsson Rosenborg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers

(2008) Guo Wang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Need for reassessment of reportedCYP2C19allele frequencies in various populations in view ofCYP2C19*17discovery: the case of Greece

(2008) Georgia Ragia et al.   PHARMACOGENOMICS